000120668 001__ 120668
000120668 005__ 20240228145459.0
000120668 0247_ $$2doi$$a10.2967/jnumed.116.183483
000120668 0247_ $$2pmid$$apmid:28062595
000120668 0247_ $$2ISSN$$a0022-3123
000120668 0247_ $$2ISSN$$a0097-9058
000120668 0247_ $$2ISSN$$a0161-5505
000120668 0247_ $$2ISSN$$a1535-5667
000120668 0247_ $$2ISSN$$a2159-662X
000120668 0247_ $$2altmetric$$aaltmetric:20896152
000120668 037__ $$aDKFZ-2017-01094
000120668 041__ $$aeng
000120668 082__ $$a610
000120668 1001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, Ali$$b0$$eFirst author$$udkfz
000120668 245__ $$aThe Clinical Impact of Additional Late PET/CT Imaging with (68)Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.
000120668 260__ $$aNew York, NY$$bSoc.$$c2017
000120668 3367_ $$2DRIVER$$aarticle
000120668 3367_ $$2DataCite$$aOutput Types/Journal article
000120668 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1509017761_1754
000120668 3367_ $$2BibTeX$$aARTICLE
000120668 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120668 3367_ $$00$$2EndNote$$aJournal Article
000120668 520__ $$aAlthough PET/CT with (68)Ga-PSMA-11 in the diagnosis of prostate cancer (PCa) is routinely performed at 1 h after injection, later scans may be beneficial because most lesions present with higher uptake and contrast. This evaluation aimed to investigate the clinical impact of additional late (68)Ga-PSMA-11 PET/CT. Methods: Between 2011 and 2016, 112 patients with PCa who underwent early (at 1 h after injection) and late (at 3 h after injection) (68)Ga-PSMA-11 PET/CT scans were retrospectively evaluated. The late scans were conducted to clarify unclear findings in early scans or to increase the probability of tumor detection in the case of negative early scans. All patients were asked to drink 1 L of water between early and late scans. In addition, 20 patients received 20 mg of furosemide before late scans. Tumor detection and radioactivity concentration within the urinary bladder were analyzed in both scans. The SUVmax and contrast of 149 tumor lesions were measured in 69 patients with pathologic findings. Results: Overall, 134 lesions characteristic for PCa in 57 patients clearly presented at 1 h after injection and 147 lesions in 68 patients at 3 h after injection. Forty-three patients showed no pathologic findings. Eight patients (7.1%) showed 1 unclear finding in early scans, which could be clarified as characteristic for PCa at 3 h after injection. Four patients (3.6%) presented with 1 lesion characteristic for PCa at 3 h after injection only. Twelve patients (10.7%) presented with 12 possible PCa lesions at 1 h after injection, which, however, could not be confirmed as PCa in late scans. Two patients presented with 1 lesion characteristic for PCa at 1 h after injection, which became invisible at 3 h after injection because of low contrast. At 3 h after injection, 62.4% of the lesions demonstrated a higher SUVmax and 65.1% a higher contrast than at 1 h after injection. Patients with furosemide presented with lower SUV and radioactivity concentration within the urinary bladder. Conclusion:(68)Ga-PSMA-11 PET/CT at 3 h after injection showed most lesions characteristic for PCa with a higher uptake and contrast. In addition, the radioactivity signal within the urinary bladder was lower at 3 h after injection, especially when furosemide was applied. Consequently, scans at 3 h after injection detected more tumor lesions than at 1 h after injection.
000120668 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000120668 588__ $$aDataset connected to CrossRef, PubMed,
000120668 650_7 $$2NLM Chemicals$$a(68Ga)Glu-urea-Lys(Ahx)-HBED-CC
000120668 650_7 $$2NLM Chemicals$$aOrganometallic Compounds
000120668 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000120668 7001_ $$aSattler, Lars Peter$$b1
000120668 7001_ $$aMier, Walter$$b2
000120668 7001_ $$aHadaschik, Boris A$$b3
000120668 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b4$$udkfz
000120668 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b5$$udkfz
000120668 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b6$$udkfz
000120668 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b7$$eLast author$$udkfz
000120668 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.116.183483$$gVol. 58, no. 5, p. 750 - 755$$n5$$p750 - 755$$tJournal of nuclear medicine$$v58$$x2159-662X$$y2017
000120668 909CO $$ooai:inrepo02.dkfz.de:120668$$pVDB
000120668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000120668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000120668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000120668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000120668 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000120668 9141_ $$y2017
000120668 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2015
000120668 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120668 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120668 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120668 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120668 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120668 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120668 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120668 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120668 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000120668 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120668 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2015
000120668 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000120668 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x1
000120668 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x2
000120668 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x3
000120668 980__ $$ajournal
000120668 980__ $$aVDB
000120668 980__ $$aI:(DE-He78)E060-20160331
000120668 980__ $$aI:(DE-He78)E050-20160331
000120668 980__ $$aI:(DE-He78)C060-20160331
000120668 980__ $$aI:(DE-He78)E030-20160331
000120668 980__ $$aUNRESTRICTED